[{"address1": "Nihonbashi Mitsui Tower", "address2": "Reception12F 1-1 Nihonbashi-Muromachi 2-chome", "city": "Chuo", "zip": "103-8324", "country": "Japan", "phone": "81 3 3281 6611", "fax": "81 3 3281 6607", "website": "https://www.chugai-pharm.co.jp", "industry": "Drug Manufacturers - General", "industryKey": "drug-manufacturers-general", "industryDisp": "Drug Manufacturers - General", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. It offers oncology products, such as Alecensa, Avastin, FoundationOne, Herceptin, Kadcyla, Perjeta, Polivy, Tecentriq, and Phesgo; Actemra for humanized anti-human IL-6 receptor monoclonal antibody; CellCept for immunosuppressant; Edirol, an osteoporosis agent; Enspryng, a pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody; Evrysdi for spinal muscular atrophy agent; Hemlibra, an anti-coagulation factor IXa/X humanized bispecific monoclonal antibody; Mircera, an erythropoiesis-stimulating agent; PiaSky, a pH-dependent binding humanized anti-complement (C5) monoclonal antibody; Ronapreve, an anti-SARS-CoV-2 monoclonal antibody; Tamiflu, an anti-influenza agent; and Vabysmo, an anti VEGF/anti Ang-2 bispecific antibody. The company has strategic alliances and collaboration with Roche Group; research collaboration and option to license agreement with Araris Biotech AG to develop ADCs using Araris AraLinQ technology; and research and license agreement with Gero PTE. LTD. to develop novel therapies for age-related diseases. The company was formerly known as Chugai Shinyaku Shokai and changed its name to Chugai Pharmaceutical Co., Ltd. in January 1943. Chugai Pharmaceutical Co., Ltd. was founded in 1925 and is headquartered in Chuo-ku, Japan. Chugai Pharmaceutical Co., Ltd. operates as a subsidiary of Roche Holding Ltd.", "fullTimeEmployees": 5026, "companyOfficers": [{"maxAge": 1, "name": "Dr. Osamu  Okuda", "age": 61, "title": "President, CEO & Chairman", "yearBorn": 1963, "fiscalYear": 2024, "totalPay": 1915344, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Iwaaki  Taniguchi", "age": 58, "title": "Executive VP, Head of Finance Supervisory Division, CFO & Director", "yearBorn": 1966, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Toshiya  Sasai", "title": "Executive of Investor Relations Group & Corporate Communications Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Nobuya  Ishii", "title": "Head of Science & Technology Intelligence Dept.", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Shinya  Takuma", "title": "VP & Head of Manufacturing Technology Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Tsukasa  Kusano", "title": "Executive VP and Head of Project & Lifecycle Management Unit", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Hitoshi  Iikura", "age": 54, "title": "Executive VP, Head of Translational Research Division & Director", "yearBorn": 1970, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Norihisa  Onozawa", "title": "Executive VP & Head of Corporate Planning Dept.", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Kae  Miyata", "title": "Head of Corporate Communications Department", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Takahiro  Mizui", "title": "Head of Clinical Development Division", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 1, "boardRisk": 8, "compensationRisk": 1, "shareHolderRightsRisk": 2, "overallRisk": 5, "governanceEpochDate": 1756684800, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://www.chugai-pharm.co.jp/hc/ss/english/ir/index.html", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 47.78, "open": 45.5, "dayLow": 45.5, "dayHigh": 45.5, "regularMarketPreviousClose": 47.78, "regularMarketOpen": 45.5, "regularMarketDayLow": 45.5, "regularMarketDayHigh": 45.5, "dividendRate": 0.67, "dividendYield": 1.48, "exDividendDate": 1767139200, "payoutRatio": 0.44529998, "beta": 0.663, "trailingPE": 27.745398, "forwardPE": 29.366882, "volume": 100, "regularMarketVolume": 100, "averageVolume": 2532, "averageVolume10days": 1940, "averageDailyVolume10Day": 1940, "bid": 42.89, "ask": 45.4, "bidSize": 100, "askSize": 200, "marketCap": 74881294336, "fiftyTwoWeekLow": 32.25, "fiftyTwoWeekHigh": 72.3, "priceToSalesTrailing12Months": 0.06259857, "fiftyDayAverage": 45.50054, "twoHundredDayAverage": 47.147717, "trailingAnnualDividendRate": 107.0, "trailingAnnualDividendYield": 2.2394307, "currency": "USD", "tradeable": false, "enterpriseValue": -953182060544, "profitMargins": 0.33058, "floatShares": 639767168, "sharesOutstanding": 1645699968, "heldPercentInsiders": 0.59911996, "heldPercentInstitutions": 0.18704, "impliedSharesOutstanding": 1655750016, "bookValue": 1206.248, "priceToBook": 0.037492286, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": -0.131, "netIncomeToCommon": 395443994624, "trailingEps": 1.63, "forwardEps": 1.54, "lastSplitFactor": "3:1", "lastSplitDate": 1593388800, "enterpriseToRevenue": -0.797, "enterpriseToEbitda": -1.619, "52WeekChange": -0.101073325, "SandP52WeekChange": 0.16885936, "lastDividendValue": 0.866, "lastDividendDate": 1750982400, "quoteType": "EQUITY", "currentPrice": 45.225, "recommendationKey": "none", "totalCash": 1027609001984, "totalCashPerShare": 624.419, "ebitda": 588812976128, "totalDebt": 0, "quickRatio": 5.012, "currentRatio": 6.037, "totalRevenue": 1196214059008, "revenuePerShare": 726.936, "returnOnAssets": 0.16052, "returnOnEquity": 0.21165001, "grossProfits": 841804021760, "freeCashflow": 343225368576, "operatingCashflow": 462121009152, "earningsGrowth": -0.131, "revenueGrowth": -0.082, "grossMargins": 0.70372003, "ebitdaMargins": 0.49223, "operatingMargins": 0.47134, "financialCurrency": "JPY", "symbol": "CHGCF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "shortName": "CHUGAI PHARMACEUTICAL CO", "longName": "Chugai Pharmaceutical Co., Ltd.", "marketState": "CLOSED", "fiftyDayAverageChange": -0.2755432, "fiftyDayAverageChangePercent": -0.0060558226, "twoHundredDayAverageChange": -1.922718, "twoHundredDayAverageChangePercent": -0.040780723, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "cryptoTradeable": false, "corporateActions": [], "regularMarketTime": 1757635200, "exchange": "PNK", "messageBoardId": "finmb_685347", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": -5.3474264, "regularMarketPrice": 45.225, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1344000600000, "regularMarketChange": -2.5550003, "regularMarketDayRange": "45.5 - 45.5", "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 2532, "fiftyTwoWeekLowChange": 12.974998, "fiftyTwoWeekLowChangePercent": 0.40232554, "fiftyTwoWeekRange": "32.25 - 72.3", "fiftyTwoWeekHighChange": -27.075005, "fiftyTwoWeekHighChangePercent": -0.37448138, "fiftyTwoWeekChangePercent": -10.107332, "dividendDate": 1504224000, "earningsTimestamp": 1761336000, "earningsTimestampStart": 1761336000, "earningsTimestampEnd": 1761336000, "earningsCallTimestampStart": 1753344000, "earningsCallTimestampEnd": 1753344000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": 1.63, "epsForward": 1.54, "displayName": "Chugai Pharmaceutical", "trailingPegRatio": 4.3655, "__fetch_time": "2025-09-13"}]